In addition, PKM2 antagonist (shikonin) and its allosteric agent (TEPP-46) substantially attenuates liver fibrosis by modulating PKM2-mediated aerobic glycolysis (Zheng et al., 2020). Here, PKM is linked to Hepatic fibrosis.